Study suggests epilepsy drug can be used to treat form of dwarfism

September 19, 2017, University of Manchester
Generalized 3 Hz spike and wave discharges in a child with childhood absence epilepsy. Credit: Wikipedia.

A drug used to treat conditions such as epilepsy has been shown in lab tests at The University of Manchester to significantly improve bone growth impaired by a form of dwarfism.

Metaphyseal chondrodysplasia type Schmid (MCDS), is a genetic condition caused by mutations in 'collagen X' which affect and .

The team are from The University of Manchester, Murdoch Children's Research Institute, Australia, and the Institute of Genetic Medicine, Newcastle University.

MCDS leads to skeletal dysplasia, commonly referred to as dwarfism, where patients are often short in stature with unusual limb proportions. There is no current treatment.

The research team discovered in lab and mouse studies that the drug carbamazepine, already approved for treating conditions such as epilepsy and bi-polar disease, can significantly reduce the effects of MCDS.

And that has opened up the possibility of human trials which, will take place at the end of this year.

Professor Ray Boot-Handford, a biochemist who led the study at The University of Manchester, said: "Carbamazepine is an inexpensive drug which has been used to treat conditions such as epilepsy and bi-polar disease for decades.

"So the possibility that it may be effective in MCDS is exciting and needs to explored further."

He added: "The indication from this study is that Carbamazepine might work in a number of other conditions where the same process involving mutant protein accumulation takes place.

"But clearly, the next stage is to test it in humans."

In the study, three weeks of treatment with carbamazepine resulted in significant increases in the rates of long bone growth, compared to untreated mice.

There was also a reduction in hip dysplasia or misalignment, a common feature of MCDS.

The researchers believe the effect occurs as the drug degrades the mutant forms of Collagen X.

This reduces stress on cells which in turn improves their ability to differentiate – improving growth.

Professor Michael Briggs, from Newcastle University, said: "The concept of going so quickly from pre-clinical data to orphan drug designation to a clinical trial is incredible.

"It exemplifies the power of drug repurposing for rare disease: there has been no involvement of big pharma and this inexpensive has had a great safety record since the 1950s."

The paper "Increased intracellular proteolysis reduces disease severity in an ER stress–associated dwarfism," is published in the Journal of Clinical Investigation.

Explore further: One-a-day anti-seizure drug shows promise for people with epilepsy

More information: Lorna A. Mullan et al. Increased intracellular proteolysis reduces disease severity in an ER stress–associated dwarfism, Journal of Clinical Investigation (2017). DOI: 10.1172/JCI93094

Related Stories

One-a-day anti-seizure drug shows promise for people with epilepsy

April 14, 2016
(HealthDay)—A once-daily epilepsy drug may control seizures just as well as a twice-daily drug, researchers report.

Decoy FGFR3 protein appears to prevent dwarfism in mice

September 24, 2013
(Medical Xpress)—A team made up of researchers from several institutions in France has found that a decoy protein injected into mice, appears to prevent the development of dwarfism. In their paper published in the journal ...

Link found between epilepsy drugs and birth defects

November 29, 2016
A joint study conducted by researchers from the universities of Liverpool and Manchester has found a link between birth defects and certain types of epilepsy medication.

Anti-epilepsy drugs can cause inflammations

December 19, 2013
Physicians at the Ruhr-Universität Bochum (RUB) have been investigating if established anti-epilepsy drugs have anti-inflammatory or pro-inflammatory properties – an effect for which these pharmaceutical agents are not ...

Recommended for you

Robots grow mini-organs from human stem cells

May 17, 2018
An automated system that uses robots has been designed to rapidly produce human mini-organs derived from stem cells. Researchers at the University of Washington School of Medicine in Seattle developed the new system.

Scientists uncover a new face of a famous protein, SWI2/SNF2 ATPase

May 17, 2018
A team of Texas A&M and Texas A&M AgriLife Research scientists now have a deeper understanding of a large switch/sucrose non-fermentable (SWI/SNF) protein complex that plays a pivotal role in plant and human gene expression ...

Antibacterial in your toothpaste may combat severe lung disease

May 17, 2018
A common antibacterial substance found in toothpaste may combat life-threatening diseases such as cystic fibrosis, or CF, when combined with an already FDA-approved drug.

Blocking two enzymes could make cancer cells mortal

May 17, 2018
EPFL scientists have identified two enzymes that protect chromosomes from oxidative damage and shortening. Blocking them might be a new anticancer strategy for stopping telomerase, the enzyme that immortalizes tumors.

Emergency contact information helps researchers branch out family tree

May 17, 2018
When you go to the doctor or hospital, one piece of information that you're always asked to provide—in addition to your name, address, and insurance information—is an emergency contact. Often, that person is a blood relative. ...

Study identifies bacterial gene responsible for producing enzyme that consumes cardiac drug

May 17, 2018
Though digoxin has been widely prescribed for decades to treat a variety of heart conditions, doctors have also long understood that, for some patients, the drug simply doesn't work.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.